New study reveals clues on the origin of Parkinson's
New research, published in the journal of Cell Death and Disease has revealed important information about the origins of Parkinson's.
New Parkinson's drug, safinamide, launched in UK
This week Zambon and Newron Pharmaceuticals launched a new Parkinson’s drug called safinamide (trade name Xadago®) in the UK.
First drug approved to treat hallucinations and delusions
On 29 May pimavanserin was approved by the US Food and Drug Administration as the first drug for treating hallucinations and delusions
Positive steps towards a blood test for Parkinson's
Research highlighted in the Guardian yesterday suggests that a blood test could be used to help detect Parkinson's.
Out now: latest Parkinson's research magazine
The spring 2016 issue of Progress, our free research magazine, is out now.
New clue in the hunt for treatments that slow ageing
New research published today has identified a vital new target in the search for treatments that can slow ageing, and could one day prevent Parkinson's.
New drug for hallucinations and delusions moves a step closer
In March the advisory panel for the US Food and Drug Administration approved a new drug for treating hallucinations and delusions in Parkinson's
First trial of stem cells for Parkinson's announced
California-based company, the International Stem Cell Corporation (ISCO), has announced the first clinical trials of a stem cell treatment for Parkinson's.
Research reveals impact of thinking difficulties on communication in Parkinson's
New research suggests that thinking difficulties may be more to blame than physical symptoms for speech problems in Parkinson's.
Common dementia drug could improve Parkinson's symptoms
Researchers at the University of Bristol have discovered that a common dementia drug, rivastigmine, could reduce falls in people with Parkinson's.